Suppr超能文献

[EZH2表达水平对原发性胃肠道弥漫性大B细胞淋巴瘤患者临床疗效及长期预后的预测价值分析]

[Analysis of the Predictive Value of EZH2 Expression Level on the Clinical Efficacy and Long-term Prognosis of Patients with Primary Gastrointestinal Diffuse Large B-cell Lymphoma].

作者信息

Lin Jian-Yang, Zheng Yan-Bin, He Hong-Ming, Wang Jie-Song, Yang Yu, Chen Dao-Guang, Zou Si-Ping, Wang Chang

机构信息

Department of Lymphoma and Head and Neck Cancer, The Affiliated Tumor Hospital of Fujian Medical University, Fuzhou 350014, Fujian Province, China.

Department of Lymphoma and Head and Neck Cancer, The Affiliated Tumor Hospital of Fujian Medical University, Fuzhou 350014, Fujian Province, China,E-mail:

出版信息

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Jun;29(3):725-730. doi: 10.19746/j.cnki.issn.1009-2137.2021.03.012.

Abstract

OBJECTIVE

To investigate the predictive value of methyltransferase EZH2 expression level on the clinical efficacy and long-term prognosis of patients with primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL).

METHODS

161 patients with newly treated PGI-DLBCL in our hospital from August 2013 to July 2019 were selected. The expression level of EZH2 protein was detected by immunohistochemistry, and the short-term efficacy and long-term survival differences of patients with different levels of EZH2 were compared. The predictive values of EZH2 expression level on the short-term efficacy and long-term prognosis of PGI-DLBCL patients were analyzed by Log-rank test and COX risk proportional regression model. Chi-square test and Logistic regression analysis were used to analyze the influencing factors of EZH2 expression level.

RESULTS

The complete response (CR) and overal response(OR) rates of those with high EZH2 expression were significantly lower than those with low EZH2 expression (P<0.001). The median OS and PFS of EZH2 high-level and low-level expression group was 37, 31 months and 49, 42 months, respectively. The cumulative OS and PFS rates of the high-level expression group were significantly lower than those of the low-level expression group, and the differences were statistically significant (P<0.05). The high expression levels of H3K27me3, EZH2, BCL-2, BCL-6, c-MYC were closely related to the shortening of OS and PFS, while the high expression level of Ki-67 was closely related to the shortening of OS (P<0.05), of which the high expression levels of H3K27me3, EZH2, BCL-2, and BCL-6 were independent risk factors for shortening of OS and PFS. The expression level of EZH2 was positively correlated with the expression level of H3K27me3, BCL-6, c-MYC and Ki-67 (r=0.741, r=0.837, r=0.809, r=0.772), and the high expression levels of H3K27me3, BCL-6 and Ki-67 were independent factors influencing the high expression of EZH2.

CONCLUSION

In patients with PGI-DLBCL, the high expression of EZH2 significantly reduces the short-term CR and OR rates, which is an independent risk factor for the shortening of long-term OS and PFS rates, and it is independently related to the high expression of H3K27me3 and BCL6.

摘要

目的

探讨甲基转移酶EZH2表达水平对原发性胃肠道弥漫大B细胞淋巴瘤(PGI-DLBCL)患者临床疗效及长期预后的预测价值。

方法

选取2013年8月至2019年7月在我院初治的161例PGI-DLBCL患者。采用免疫组织化学法检测EZH2蛋白表达水平,比较不同EZH2水平患者的短期疗效及长期生存差异。采用Log-rank检验和COX风险比例回归模型分析EZH2表达水平对PGI-DLBCL患者短期疗效及长期预后的预测价值。采用卡方检验和Logistic回归分析EZH2表达水平的影响因素。

结果

EZH2高表达者的完全缓解(CR)率和总缓解(OR)率显著低于EZH2低表达者(P<0.001)。EZH2高水平和低水平表达组的中位总生存期(OS)和无进展生存期(PFS)分别为37、31个月和49、42个月。高水平表达组的累积OS率和PFS率显著低于低水平表达组,差异有统计学意义(P<0.05)。H3K27me3、EZH2、BCL-2、BCL-6、c-MYC的高表达水平与OS和PFS缩短密切相关,而Ki-67的高表达水平与OS缩短密切相关(P<0.05),其中H3K27me3、EZH2、BCL-2和BCL-6的高表达水平是OS和PFS缩短的独立危险因素。EZH2表达水平与H3K27me3、BCL-6、c-MYC和Ki-67的表达水平呈正相关(r=0.741,r=0.837,r=0.809,r=0.772),H3K27me3、BCL-6和Ki-67的高表达水平是影响EZH2高表达的独立因素。

结论

在PGI-DLBCL患者中,EZH2高表达显著降低短期CR率和OR率,是长期OS率和PFS率缩短的独立危险因素,且与H3K27me3和BCL6的高表达独立相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验